By Business/Source
Currency:USD
2025/Q3
Stock NameRevenueRatio
Business of developing and commercializing innovative ophthalmic products for the treatment of eye966K100.00%
By Country/Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States (U.S)42.05M97.17%
China1.12M2.60%
United Kingdom (U.K)100K0.23%